BIOMARIN PHARMACEUTICAL INC (BMRN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for BIOMARIN PHARMACEUTICAL INC (BMRN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 46/100 — a percentile rank of BIOMARIN PHARMACEUTICAL INC’s fundamentals against Manufacturing peers, weakest on financial health. A quality ranking, not a price prediction.
| Market cap | $11.3B |
| P / E | 155.0× |
| P / S | 3.3× |
| EV / EBITDA | 47.9× |
| Gross margin | 76.1% |
| Operating margin | 4.5% |
| Net margin | 2.1% |
| Return on equity | 1.1% |
| ROIC | 0.8% |
| Revenue growth | 11.2% |
| Debt / equity | 0.7× |
| Dividend yield | 0.0% |
Is BIOMARIN PHARMACEUTICAL INC overvalued? P/E looks fair vs its 5-year range; P/S looks undervalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from BIOMARIN PHARMACEUTICAL INC’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact